Pharmacological inhibition of ULK-1 when combined with TKI treatment reduces growth of a CML cell line and patient-derived xenografted CML cells in mouse models [30]. This evidence concerns the gene ULK1 and chronic myelogenous leukemia, BCR-ABL1 positive.